Unwanted side-effects in trials have been found as follows:
Delayed hypersensitivity reactions have been reported in Crohn's disease patients restarted on infliximab 2-4 years after an initial course.
In a study pf 428 patients given infliximab 53-68% developed antinuclear antibodies (vs 26% on placebo plus methotrexate), and 7-11% developed anti dsDNA antibodies.
A lupus-like syndrome has been described with infliximab and if this occurs the drug should be discontinued.
Risk of malignancy:
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.